Dr Reddys Laboratories (RDY) EBIT (2009 - 2023)

Dr Reddys Laboratories' EBIT history runs 15 years deep, the most recent figure standing at $215.0 million for Q2 2023.

• On a quarterly basis, EBIT changed N/A year-over-year to $215.0 million in Q2 2023; TTM through Jun 2023 was $741.0 million, a N/A change from a year earlier, with the FY2026 full-year figure at $539.0 million, down 35.99% from the prior year.
• EBIT grew to $215.0 million in Q2 2023 per RDY's latest filing, from $212.0 million in the prior quarter.
• Across five years, EBIT topped out at $215.0 million in Q2 2023 and bottomed at -$82.0 million in Q3 2019.
• The 5-year median for EBIT is $112.0 million (2020), against an average of $99.5 million.
• Across the five-year window, EBIT soared 47.14% in 2019 and decreased 19.09% in 2021, its largest moves.
• Year by year, EBIT stood at -$82.0 million in 2019, then rose by 2.44% to -$80.0 million in 2020, then soared by 303.75% to $163.0 million in 2021, then decreased by 7.36% to $151.0 million in 2022, then jumped by 42.38% to $215.0 million in 2023.
• Per Business Quant, the three latest RDY EBIT figures stand at $215.0 million (Q2 2023), $212.0 million (Q1 2023), and $151.0 million (Q4 2022).